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Currently, little is known about the extent of inter-individual variability in response to 
beta-alanine (BA) supplementation, nor what proportion of said variability can be 
attributed to external factors, or to the intervention itself (intervention response). To 
investigate this, individual participant data on the effect of BA supplementation on a high 
intensity cycling capacity test (CCT110%) were meta-analysed. Changes in time to 
exhaustion (TTE) and muscle carnosine (MCarn) were the primary and secondary 
outcomes. Multi-level distributional Bayesian models were used to estimate the mean and 
standard deviation of BA and placebo (PLA) group change scores. The relative sizes of 
group standard deviations were used to infer whether observed variation in change scores 
were due to intervention or non-intervention related effects. Six eligible studies were 
identified, and individual data were obtained from four of these. Analyses showed a group 
effect of BA supplementation on TTE (7.7[95%CrI:1.3 to 14.3 s]) and MCarn 
(18.1[95%CrI:14.5 to 21.9 mmol·kgDM-1]). A large intervention response variation was 
identified for MCarn (𝜎𝜎𝐼𝐼𝐼𝐼= 5.8 [95%CrI: 4.2 to 7.4 mmol·kgDM-1]); however, equivalent 
change score standard deviations were shown for PLA (16.1[95%CrI:13.0 to 21.3 s]) and 
BA (15.9[95%CrI:13.0 to 20.0 s] conditions, with the probability that standard deviation 
was greater in PLA being 0.64. In conclusion, the similarity in observed change score 
standard deviations between groups for TTE indicates the source of variation is common 
and therefore unrelated to BA supplementation, likely originating instead from external 
factors, which may include, for example, nutritional intake, sleep patterns or training 
status. 
 





Beta-alanine (BA) supplementation is an established nutritional strategy to improve 
exercise capacity (Saunders et al., 2017a). This is likely due to its capacity to increase 
muscle carnosine content (Rezende et al., 2020), which acts as an intracellular buffering 
agent (Blancquaert et al., 2015; Dolan et al., 2019; Trexler et al., 2015). A recent meta-
analysis provided evidence that BA supplementation exerted a positive, albeit small 
magnitude effect (d = 0.18) across a range of exercise protocols, while meta-regression 
identified that exercise type and duration were influential moderating factors, with BA 
exerting its greatest influence on exercise capacity-based tests lasting between 30 seconds 
and 10 minutes (d = 0.49) (Saunders et al., 2017a). These results align with plausible 
physiological mechanisms, given that capacity-based tests of moderate duration are most 
likely to be limited by metabolic acidosis (Bishop et al., 2009). Despite this evidence of 
a positive average effect at the group level, substantial variability in performance 
outcomes was identified between studies. For example, both positive and null effects were 
reported for the influence of BA on an isometric endurance hold test (Bassinello et al., 
2019; Derave et al., 2007; Jones et al., 2017; Sale et al., 2012) or on a high intensity 
cycling capacity test (the CCT110%) (Danaher et al., 2014; Hill et al., 2007; Patel et al., 
2021; Sale et al., 2011; Saunders et al., 2017b; Yamaguchi et al., 2020). Both these tests 
should theoretically be amenable to BA supplementation, given that they are exercise 
capacity tests that induce large pH perturbations and are within the time-durations most 
likely to be positively influenced by BA supplementation (Saunders et al., 2017a).  
 
Research investigating BA supplementation has also highlighted large within-study inter-
individual variability. For example, in addition to reporting that BA moderately improved 
CCT110% performance for the group, Saunders et al. (Saunders et al., 2017b) also 
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identified a wide range of individual changes, with some participants demonstrating 
apparently large performance improvements (up to 40 seconds), while others showed 
none, or even a worsening of performance (up to -20 seconds).  
 
Large inter-individual variability is not limited to BA supplementation studies, but is 
likely to apply to most health and performance related interventions (Atkinson & 
Batterham, 2015). Improved understanding of the factors underpinning this variability 
could improve study standardization and intervention effectiveness, enabling more 
targeted recommendations, as well as the opportunity for individualized advice and 
prescription. Investigation of individual response variation is, however, both 
methodologically and statistically challenging, as has been described in detail elsewhere 
(Atkinson et al., 2019; Atkinson & Batterham, 2015; Bonafiglia et al., 2019; Hecksteden 
et al., 2015; Senn, 2004; Swinton et al., 2018). Briefly, variance in observed change scores 
across an intervention generally comprises three sources (Atkinson & Batterham, 2015; 
Swinton et al., 2018) including measurement error (which comprises instrumentation 
noise and biological noise, both of which may cause day to day fluctuations in the 
observed score, even though the true score remains constant); biological variability 
(which represents actual change in true score across the intervention period, but which 
occurs independently of the intervention); and intervention response variation (which 
represents variation directly attributable to the investigated intervention). Theoretically, 
variation in the observed change scores of the control group will comprise measurement 
error and biological variability, whilst variation in the intervention group will comprise 
all three sources. As such, inclusion of a control group enables estimation of the variation 




Currently, little is known about the extent to which variation in observed changes in 
response to BA supplementation are directly attributable to the intervention. Accurate 
estimation of inter-individual variability is, however, likely to require relatively large 
sample sizes which may not be feasible in single studies due to costs, need for invasive 
procedures and/or time constraints. Additionally, estimation is particularly challenging in 
studies of ergogenic aids as expected effects tend to be small (Saunders et al., 2017a), 
while performance related outcomes can be influenced by substantive measurement error 
and biological variability. Statistical meta-analysis presents an approach to mitigate the 
limitations of small effects, noisy measurement outcomes and small sample sizes by 
pooling data across studies to better estimate parameters of interest (Page et al., 2020). 
Most meta-analyses are, however, based upon aggregate data and can only provide 
information on the mean response. In contrast, individual participant data (IPD) meta-
analyses which source raw data from previous studies, have been described as the “gold-
standard” of meta-analytic approaches because they allow for assessment of participant 
level effects and interactions (Kelley & Kelley, 2019). Accordingly, we conducted an IPD 
meta-analysis, the aim of which was to estimate the mean response to BA 
supplementation on high intensity cycling capacity and to quantify individual response 
variation (namely that attributable to the BA intervention itself). 
 
Methods 
This meta-analysis was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Moher et al., 2009). 
Eligibility criteria were defined according to the Population, Intervention, Comparator, 
Outcomes and Study Design (PICOS), as described in Table 1. Only studies that used the 
CCT110% —a high-intensity cycling capacity test in which individuals are required to 
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cycle at 110% of their previously stablished maximal power output (Wmax) until volitional 
exhaustion—were included. This test was selected as a model for this analysis because it 
is a widely used protocol in which a positive response to BA supplementation would be 
expected (Saunders et al., 2017a). 
 
Search strategy and data extraction  
To identify eligible studies, the included studies from a previous meta-analysis of all 
double-blind placebo-controlled trials that investigated the influence of BA 
supplementation on exercise test performance were screened (Saunders et al., 2017a). The 
full search strategy is described in the previous meta-analysis. Three databases (PubMed, 
Google Scholar and Web of Science) were searched using the terms “β-alanine OR beta-
alanine” concatenated with “supplementation OR exercise OR training OR athlete OR 
performance OR carnosine” and only double-blinded, placebo-controlled trials were 
selected. The same strategies were repeated in September 2020 to identify any additional 
studies that had been published in the interim. Aggregate data were extracted from studies 
that matched our inclusion criteria (Table 1). Authors were contacted to request individual 
participant data, and these were compiled into a pre-piloted excel spreadsheet.  
 
Risk of bias and certainty in cumulative outcomes:  
Certainty in systematic review outcomes (namely each combined meta-analytic result 
based upon all available data sets) was ascertained using the recommendations of the 
Grading of Recommendations, Assessment, Development and Evaluations (GRADE) 
working group (Guyatt et al., 2008). Five potential downgrading factors were considered, 
namely risk of bias (assessed using the Cochrane Collaborations RoB2 tool (Sterne et al., 
2019)), indirectness, inconsistency, imprecision and publication bias. Potential upgrading 
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factors included large effects, evidence of a dose-response or the presence of plausible 
residual confounding factors (Guyatt et al., 2008). All studies in the current review were 
initially defined as “high certainty” given that only double-blinded, randomized, placebo-
controlled designs were included in the review. Application of the GRADE strategy 
subsequently allowed for this a-priori certainty rating of “high” to be maintained, or to 
be downgraded to “moderate”, “low” or “very low”.  
 
Statistical analysis 
The present study comprised both aggregate and individual participant data meta-analyses 
from a Bayesian perspective. Analyses were performed on change in TTE performance 
(s) as the primary outcome, and change in MCarn (mmol·kgDM-1) as the secondary 
outcome. For aggregate analyses, placebo controlled mean difference and variance 
difference effect sizes were calculated to describe the effects of supplementation on mean 
response and response variation, respectively. Calculated values were pooled using three-
level hierarchical models including random effects to account for within studies variation, 
between studies variation (𝜏𝜏) and covariance (𝐼𝐼𝐼𝐼𝐼𝐼) of multiple outcomes reported in the 
same study. Standard errors for mean differences (Morris & DeShon, 2002) and variance 
differences (Williamson et al. 2018) were calculated according to previously described 
formulas. The required pre-post correlation for mean difference standard errors was 
estimated from available data and set to 0.5 for both outcome variables. Response 
variation estimates were transformed by taking the square root (𝜎𝜎𝐼𝐼𝐼𝐼) of the absolute 
variance values and then reapplying the positive or negative sign (Williamson et al. 2018).   
Individual participant data meta-analyses were conducted by calculating observed change 
scores from baseline and fitting hierarchical distributional models enabling both the 
location (mean) and spread (standard deviation) to be estimated assuming Gaussian 
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distributions. Models for both the mean and standard deviation included a group factor 
(placebo vs intervention) and for the mean a participant random effect intercept was 
added. Moderator analyses investigating group level characteristics were completed for 
total BA consumption in both outcome variables. However, moderator analyses for 
individual variation in the primary outcome (TTE performance change) were only 
conducted where evidence was obtained that variation was influenced directly by the 
intervention (Atkinson & Batterham, 2015). Inferences from all analyses were performed 
on posterior samples generated using the Hamiltonian Markov Chain Monte Carlo 
method (five chains, 100,000 iterations and 50,000 warmup). Interpretations were based 
on the median value (0.5-quantile) and credible interval (CrI). Additionally, posterior 
samples were used to estimate the proportion of individuals that would observe a small, 
medium and large change (small: 0.2; medium: 0.5; and large: 0.8 times baseline standard 
deviation), and the probability that the intervention change score standard deviation was 
larger than placebo for individual participant data analyses. Analyses were performed 
using the R wrapper package brms interfaced with Stan to perform sampling (Bürkner, 
2017). Convergence of parameter estimates was obtained for all models with Gelman-




Overview of available studies 
Six studies that investigated the influence of BA supplementation on performance in the 
CCT110% were identified (Danaher et al., 2014; Hill et al., 2007; Patel et al., 2021; Sale et 
al., 2011; Saunders et al., 2017b; Yamaguchi et al., 2020). All corresponding authors were 
contacted, and individual participant data from four studies were obtained (Patel et al., 
2021; Sale et al., 2011; Saunders et al., 2017b; Yamaguchi et al., 2020). A summary of 
the study design, population and dosing protocol of all included studies is available in 
Table 2. The CCT110% protocols employed were compared to the standard protocol  
described in a reliability study of the CCT110% (Saunders et al., 2013) (see Supplementary 
File 1). The differences between study designs were minor, and deemed unlikely to 
impact interpretation of the results, particularly given that each study contained its own 
placebo-controlled comparison group who underwent an identical protocol to the BA 
group.  
 
Influence of BA supplementation on Time to Exhaustion in the CCT110% (primary 
outcome) 
Aggregate data for mean difference effect sizes were obtained for five studies (Hill et al., 
2007; Patel et al., 2021; Sale et al., 2011; Saunders et al., 2017b; Yamaguchi et al., 2020) 
generating a total of 11 placebo-controlled effect sizes. One study was not included 
(Danaher et al., 2014) because no pre-supplementation data for TTE was available. This 
study did, however, report a positive influence of BA on this outcome when compared to 
placebo (p = 0.005) (Danaher et al., 2014).  Using the aggregate data, a large absolute 
mean difference effect size was estimated (𝐸𝐸𝑆𝑆0.5 = 11.9 [95%CrI: 6.3 to 16.5 s]; Figure 
1 A) with relatively low between study variance (𝜏𝜏0.5 = 2.4 [75%CrI: 0.5 to 6.1 s] and 
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covariance due to reporting of multiple timepoints (𝐼𝐼𝐼𝐼𝐼𝐼0.5 = 0.13 [75%CrI: 0.02 to 
0.36]). Evidence of a group level moderating effect was identified for total BA 
consumption. The mean difference between groups in time to exhaustion with a 
cumulative dose of 500 g was estimated to be 7.4 [95%CrI: 0.8 to 13.9 s], with linear 
regression estimating a 0.6 [95%CrI: 0.03 to 1.2 s]) increase per additional 100 g 
consumed. Aggregate data for response variation were calculated for four studies  (Patel 
et al., 2021; Sale et al., 2011; Saunders et al., 2017b; Yamaguchi et al., 2020) generating 
a total of 9 effect sizes. Large credible intervals were obtained indicating equivalence or 
potentially greater variation in the placebo group (𝜎𝜎𝐼𝐼𝐼𝐼= -6.1 [95%CrI: -15.5 to 11.7 s]; 
𝜏𝜏0.5 = 10.4 [75%CrI: 5.1 to 15.3 s]; 𝐼𝐼𝐼𝐼𝐼𝐼0.5 = 0.12 [75%CrI: 0.01 to 0.30]). 
 
Individual participant data were obtained for four studies (Patel et al., 2021; Sale et al., 
2011; Saunders et al., 2017b; Yamaguchi et al., 2020) generating 210 sets of pre, 
intermediate and post-test data (127 BA, 83 placebo) across 78 participants (46 BA, 32 
placebo). Using the distributional model, the mean difference in time to exhaustion with 
BA compared to placebo was estimated to be 7.7 [95%CrI: 1.3 to 14.3 s] (Figure 1 B), 
with very large individual random effect intercepts estimated (14.1 [95%CrI: 10.6 to 16.8 
s]). In agreement with the aggregate analysis, the distributional model estimated 
equivalent standard deviation of change scores in the combined placebo (16.1 [95%CrI: 
13.0 to 21.3 s]) and supplement (15.9 [95%CrI: 13.0 to 20.0 s] analysis, with the 
probability that the standard deviation was greater in the placebo group being 0.643. 
Using the distributional model estimates, the proportion of individuals expected to make 
at least a small, medium, and large improvement were substantively greater for BA 
supplementation (small: 0.63 [95%CrI: 0.42 to 0.81]; medium: 0.52 [95%CrI: 0.31 to 
0.72]; and large: 0.42 [95%CrI: 0.22 to 0.62]) compared to placebo (small: 0.45 [95%CrI: 
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0.24 to 0.66]; medium: 0.35 [95%CrI: 0.17 to 0.56]; and large: 0.26 [95%CrI: 0.11 to 
0.45]). No moderator analyses for individual variation were investigated due to the 
similarity in change score standard deviations (Williamson et al., 2018).   
 
Influence of BA supplementation on MCarn (secondary outcome) 
MCarn aggregate data were obtained for four studies (Danaher et al., 2014; Hill et al., 
2007; Saunders et al., 2017b; Yamaguchi et al., 2020) generating a total of 10 placebo-
controlled effect sizes. A large absolute mean difference effect size was identified 
𝐸𝐸𝑆𝑆0.5 = 13.7 [95%CrI: 7.7 to 19.6 mmol·kgDM-1] with moderate between study variance 
(𝜏𝜏0.5 = 4.2 [75%CrI: 0.3 to 12.0 mmol·kgDM-1]) and substantive covariance due to the 
reporting of multiple timepoints (𝐼𝐼𝐼𝐼𝐼𝐼0.5 = 0.55 [75%CrI: 0.23 to 0.82]). Evidence of a 
group level moderating effect was identified for total BA consumption. The mean 
difference in MCarn with a cumulative dose of 500 g was estimated to be 15.1 [95%CrI: 
10.7 to 19.5 mmol·kgDM-1], with linear regression estimating a 0.36 [95%CrI: 0.09 to 
0.6 mmol·kgDM-1]) increase per additional 100 g. Aggregate data for response variation 
were calculated for two studies (Saunders et al., 2017b; Yamaguchi et al., 2020) 
generating a total of 7 effect sizes. Evidence was obtained indicating a large response 
variation (𝜎𝜎𝐼𝐼𝐼𝐼= 5.8 [95%CrI: -2.4 to 8.4 s]; 𝜏𝜏0.5 = 3.9 [75%CrI: 1.9 to 6.5 s]; 𝐼𝐼𝐼𝐼𝐼𝐼0.5 = 
0.18 [75%CrI: 0.01 to 0.38]) 
 
Individual participant data on the MCarn response to supplementation were obtained for 
two studies (Saunders et al., 2017b; Yamaguchi et al., 2020), generating 156 sets of pre-
post data (101 BA, 55 placebo) across 39 individuals (26 BA, 13 placebo). The mean 
difference in MCarn in the supplement condition compared to placebo was estimated to 
be 18.1 [95%CrI: 14.5 to 21.9 mmol·kgDM-1], with individual random effect intercepts 
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estimated as 4.3 [95%CrI: 3.0 to 6.0 mmol·kgDM-1]. When pooling data across studies 
using the distributional model, the intervention response standard deviation was estimated 
as 5.8 (95%CrI: 4.2 to 7.4 mmol·kgDM-1).  
 
Certainty in outcomes 
All outcomes were assigned an a-priori certainty rating of “high” because they were all 
based upon data from double-blinded, randomized, placebo-controlled trials (as defined 
by the eligibility criteria). Results of the RoB2 assessment are summarised in Figure 2 
(generated using R package robvis (McGuinness & Higgins, 2021)). Possible sources of 
bias included a lack of information on specific randomization and concealment 
approaches (Domain 1) (Danaher et al., 2014; Hill et al., 2007; Sale et al., 2011); non-
reporting of adherence or compliance information (Domain 2) (Danaher et al., 2014; Hill 
et al., 2007); and lack of information about the extent of, or reasons for, participant 
withdrawal (Domain 3) (Danaher et al., 2014; Hill et al., 2007; Sale et al., 2011; Saunders 
et al., 2017b). Additionally, no study provided a preregistered protocol or analysis plan 
(Domain 5). These issues were largely due to a lack of detail in reporting, and were 
deemed unlikely to meaningfully bias the available data. As such, certainty in outcomes 
were not downgraded due to RoB2 (The complete analysis and decision rationale is 
available in Supplementary File 2). The studies in this review used commonly 
recommended dosing protocols, and were conducted on young, healthy, recreationally 
active but non-specifically trained men and so were not downgraded based upon 
indirectness, but downgrading of certainty in these outcomes may be advisable for 
investigators interested in other populations, e.g., highly trained athletes. All MCarn 
outcomes, and the influence of total BA consumption on TTE performance were 
downgraded due to potential imprecision as they were based upon a subset of the available 
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data. MCarn outcomes were subsequently upgraded, however, because they were 
consistent with recent meta-analytic results based upon all available data related to the 
MCarn response to BA supplementation (Rezende et al., 2020), thus leading to a greater 
level of certainty in the results obtained. Overall, the majority of outcomes were deemed 
to have a “High” degree of certainty, with the exception of the influence of total BA 
consumption on TTE, which was deemed to be of “Moderate” certainty (Table 3). 
 
Discussion 
The principal finding of this investigation was the lack of intervention response variation 
to BA supplementation on high-intensity cycling performance. Large, but similar, 
variances in individual change scores were observed for both the BA and placebo groups, 
indicating that variation in response to the intervention itself had a negligible 
contribution, meaning that observed changes were mainly attributable to factors common 
to both groups, namely measurement error (instrument and biological noise) and/or 
biological variability.  
 
The finding of a positive effect of BA supplementation on MCarn aligns with previous 
research (Harris et al., 2006; Rezende et al., 2020) and confirms that the biological 
mechanism for improved performance was present. Comparisons between BA and 
placebo groups identified a large intervention response standard deviation for MCarn 
changes (𝜎𝜎𝐼𝐼𝐼𝐼 = 5.8 (95%CrI: 4.2 to 7.4 mmol·kgDM-1), demonstrating that a substantial 
proportion of observed variation was attributable to the intervention itself, which may 
relate to factors involved in the biokinetics of MCarn synthesis, such as the rate of BA 
uptake to the skeletal muscle, or the activity level of the synthesizing enzyme carnosine 
synthase, or in intervention adherence. Previous research also indicates that BA 
14 
 
supplementation has a large effect on MCarn (Rezende et al., 2020), and that in the 
absence of intervention, MCarn remains relatively stable across similar time periods as 
were investigated herein (Baguet et al., 2009; da Eira Silva et al., 2020; Rezende et al., 
2020). Both factors (large effect and small biological variation) may facilitate 
identification of intervention response variation. In contrast, whilst large variations in 
observed change scores were also observed for TTE, comparisons between BA and 
placebo groups revealed similar standard deviations. This finding indicates that 
intervention response variation is negligible, and that observed variation must be 
primarily attributable to factors common to both the placebo and BA group (namely 
measurement error and biological variability). These differences in individual response 
findings for MCarn and TTE highlight the importance of not conflating mechanistic and 
performance outcomes – just because the biological mechanism to improve exercise 
performance is present, does not necessarily mean that all individuals will experience an 
associated magnitude dependent performance improvement.  
 
The finding of a group effect for BA supplementation on performance on this high-
intensity capacity test, along with negligible individual response variation, has positive 
implications for individuals who supplement with BA, as it suggests there is a consistent 
group effect and that most individuals who supplement will have the capacity to improve 
performance. This does not mean, however, that everyone who supplements will record 
improvements in performance. As evidenced by the large inter-individual variation 
observed (see Figure 1), large measurement errors and true changes (both positive and 
negative) in performance can be caused by sources external to the supplement. Although 
beyond the scope of the current investigation to parse out the relative contribution of 
potential factors underpinning this variation, it seems unlikely that the instrumentation 
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noise component of measurement error would noticeably impact performance. As such, 
biological noise (i.e., biological factors that cause the observed score to fluctuate even 
though the true score remains stable) and biological variability (actual change in the true 
score due to factors outside the intervention) are the most likely explanations for this 
finding. Similar findings of negligible variation attributable to the intervention itself has 
been reported in other interventions (Islam & Gurd, 2020), including the effect of exercise 
training on VO2max (Williamson et al., 2017) and weight loss (Williamson et al., 2018), 
in a pain management intervention in adults with chronic musculoskeletal pain (Watson 
et al., 2021), and in changes in muscle size and strength following resistance training 
(Dankel et al., 2020). Collectively, these findings support consideration of more holistic 
approaches to intervention delivery.  
 
Factors that may potentially influence an individual’s response to intervention include 
nutritional status (both acute and chronic), physical activity levels, sleep, environmental 
conditions and external sources of motivation (Mann et al., 2014), such as intervention 
expectancy (Marticorena et al., 2021). A logical next step for future research would be to 
attempt to parse out the relative influence of these factors on individual response 
variation, although this is undoubtedly challenging. Initially, parameters of interest must 
be defined. For example, although it seems logical to predict that factors such as 
nutritional intake may contribute to observed variability, the precise parameters required 
to test this hypothesis remains to be determined (e.g., macronutrient composition? 
Micronutrient adequacy? Energy availability?). It is also important to consider whether 
parameters of interest can be measured with a reasonable level of accuracy. Further 
complicating these assessments is the possibility that a combination of factors, exerting 
potentially opposing directional effects, is likely to underpin observed variation, in which 
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case very large samples, in combination with sophisticated analysis techniques, may be 
necessary to parse out their relative contribution. Sampling error can lead to different 
outcomes between studies, and this is particularly relevant when investigating small 
effects and large variability (as is common in sport supplement interventions) and 
therefore results from any one study should be interpreted with caution. Strategies to 
increase sample size and thereby to reduce sampling error (for example through multi-
centre studies or individual participant data meta-analyses as was conducted herein) may 
be required to further advance understanding of factors underpinning individual variation. 
Similarly, reducing measurement error through selection of the most reliable tests, 
rigorous control and standardization of potential confounding variables, as have been 
described elsewhere (Betts et al., 2020; Burke & Peeling, 2018),  along with increased 
testing may also facilitate further investigation of individual response variation.  
 
The findings of the present study may have been influenced by the combination of 
relatively small mean intervention response alongside large measurement error. In 
contrast, studies investigating interventions with larger mean responses and lower 
measurement error may have greater precision to quantify the different error sources and 
potentially identify intervention response variation. It would also be interesting to 
investigate whether population characteristics impact findings. The participants 
investigated herein were all young, healthy, active men, but they were not trained cyclists. 
Replication of these analyses in elite athletes, who may, theoretically, be less subject to 
both measurement error and external sources of variation (by having more consistent 
sleep, nutrition and training habits), may potentially allow for detection of variation 




Summary and Conclusion  
In both aggregate and individual participant data meta-analyses we identified a positive 
mean effect of BA supplementation on high-intensity cycling capacity as determined by 
the CCT110% test, although there was considerable inter-individual variability in the 
observed change. The extent of this variation was similar between the placebo and BA 
groups, indicating that it was mainly due to factors common to both groups and with 
minimal contribution attributable to the BA intervention itself. Individuals who wish to 
supplement with BA should follow evidence-based dosing protocols (e.g., to ingest 3.2 – 
6.4 g·day-1 of BA for at least 4 weeks). In addition to following dosing recommendations, 
each individual should consider other modifiable lifestyle factors in order to enhance their 
own likelihood of a positive response, which includes, for example, maintaining dietary 
habits that support energy and nutrient requirements, recommended physical activity 
levels and adequate sleep schedules.  
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Table 1: Inclusion and exclusion criteria according to PICOS  
Population Healthy participants of any age or physical activity level. 
Intervention Studies investigating the effects of chronic BA supplementation (≥ 4 
weeks) on exercise test performance. 
Comparator Change in the BA group versus placebo.  
Outcomes The primary outcome of interest was change in TTE in the CCT110% 
test, along with individual response variation. Changes in MCarn 
content were considered a secondary outcome, along with the proposed 
moderator analyses described in the analysis section. 




Table 2: Characteristics of Included Studies 1 
Author (date)  Study design  Population  Dosing Protocol  
Hill et al. (2007) Double blinded RCT, with tests conducted 
after 0, 4, 8 and 10 weeks of 
supplementation.  
Healthy, physically active males (BA n 
= 13; PLA n = 12). 
BA: Week 1: 4 g·day-1. Week 2: 4.8 g·day-1. Week 3: 5.6 
g·day-1. Week 4: 6.4 g·day-1. Dose maintained until 
week 10 for 8 participants (8 x 800 mg doses) (total dose 
= 145.6 g). PLA: maltodextrin. 
Sale et al. (2011) Double blinded RCT, with tests conducted 
after 0 and 4 weeks of supplementation.  
Healthy, physically active males (BA n 
= 10; PLA n = 10). 
BA: 6.4g·day-1 (4 x 1600 mg) for 4 weeks (total dose = 
179.2 g). PLA: maltodextrin. 
Danaher et al. (2014) Double blinded, within subject cross-over, 
RCT, with test sessions separated by a 12-
week washout.  
Healthy, physically active males (n = 8). BA: 4.8 g·day-1 (6 x 800 mg) for 4 weeks, then 6.4 g·day-
1 (8 x 800 mg) for 2 weeks (total dose = 224 g). PLA: 
calcium carbonate.  
Saunders et al. (2017) Double blinded RCT, with tests conducted 
after 0, 4, 8, 12, 16, 20, and 24 weeks of 
supplementation.  
Healthy, physically active males (BA n 
= 15; PLA n = 9). 
BA: 6.4 g·day-1 of BA (4 x 1600 mg) for 24 weeks (total 
dose = 1075.2 g). PLA: maltodextrin.  
Yamaguchi et al. (2020) Double blinded RCT, with tests conducted 
after 0 and 8 weeks of supplementation. 
Healthy, physically active, omnivorous 
males (BA n = 11; PLA n = 4). 
BA: 6.4 g·day-1 (4 x 1600 mg) for 8 weeks (total dose = 
358.4 g). PLA: maltodextrin. 
Patel et al. (2021) Double blinded RCT, with tests conducted 
after 0 and 4 weeks of supplementation.   
Healthy, physically active, omnivorous 
males (BA n = 10; PLA n = 9)  
BA: 6.4 g·day-1 (4 x 1600 mg) for 4 weeks (total dose = 




Table 3: GRADE Quality assessment and summary of findings 3 
Quality assessment       Summary of findings   
       Number of participants   
Outcome (No. of studies) ROB Consistency Precision Publication Bias Upgrade  BA PLA Effect size (95% CrI) Quality 
TTE main effect of BA (AD) (5) ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁  59 44 11.9 (6.3–16.5) s ⨁⨁⨁⨁ 
High 




TTE influence of total BA 
consumption (500g) (2) 
⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁◯ ⨁⨁⨁◯ ⨁⨁⨁◯  26 13 7.4 (0.8–13.9) s ⨁⨁⨁◯ 
Moderate 
TTE response variation (𝜎𝜎𝐼𝐼𝐼𝐼) (4) ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁ ⨁⨁⨁⨁  46 32 - ⨁⨁⨁⨁ 
High 








MCarn influence of total BA 
consumption (500g) (2) 








⨁⨁⨁⨁ = High; ⨁⨁⨁◯ = Moderate; ⨁⨁◯◯ = Low; ⨁◯◯◯ = Very Low. ROB = Risk of Bias; AD = Aggregate Data; IPD = Individual Participant Data; 𝜎𝜎𝐼𝐼𝐼𝐼  4 
= Intervention Response Standard Deviation. 5 
Figure 1
Figure 1. Influence of BA Supplementation on TTE. Panel A represents aggregate data from placebo-controlled trials, showing mean difference effect sizes along with 95% credible 
intervals for the shrunken effects of BA supplementation on TTE after applying the meta-analysis model. Panel B represents individual participant data with BA supplementation and 
placebo means along with 95% credible intervals.
Figure 2
Figure 2. Risk of bias in individual studies.
